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RAF kinase inhibitor-independent constitutive activation of
Yes-associated protein 1 promotes tumor progression in thyroid cancer
SE Lee1,7, JU Lee2,7, MH Lee1, MJ Ryu1, SJ Kim1, YK Kim1, MJ Choi1, KS Kim1, JM Kim3, JW Kim4, YW Koh5, D-S Lim6, YS Jo1 and M Shong1
The transcription coactivator Yes-associated protein 1 (YAP1) is regulated by the Hippo tumor suppressor pathway. However, the
role of YAP1 in thyroid cancer, which is frequently associated with the BRAFV600E mutation, remains unknown. This study aimed to
investigate the role of YAP1 in thyroid cancer. YAP1 was overexpressed in papillary (PTC) and anaplastic thyroid cancer, and nuclear
YAP1 was more frequently detected in BRAFV600E (þ ) PTC. In the thyroid cancer cell lines TPC-1 and HTH7, which do not have the
BRAFV600E mutation, YAP1 was cytosolic and inactive at high cell densities. In contrast, YAP1 was retained in the nucleus and its
target genes were expressed in the thyroid cancer cells 8505C and K1, which harbor the BRAFV600E mutation, regardless of cell
density. Furthermore, the nuclear activation of YAP1 in 8505C was not inhibited by RAF or MEK inhibitor. In vitro experiments, YAP1
silencing or overexpression affected migratory capacities of 8505C and TPC-1 cells. YAP1 knockdown resulted in marked decrease
of tumor volume, invasion and distant metastasis in orthotopic tumor xenograft mouse models using the 8505C thyroid cancer cell
line. Taken together, YAP1 is involved in the tumor progression of thyroid cancer and YAP1-mediated effects might not be affected
by the currently used RAF kinase inhibitors.
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INTRODUCTION
Thyroid cancer is the leading cause of morbidity and mortality for
endocrine malignancies. Papillary thyroid cancer (PTC) is the most
common thyroid cancer and is the result of the abnormal
activation of the MEK/ERK signaling pathway.1 The frequent
genetic alterations, RET/PTC rearrangements, Ras mutations and
BRAFV600E mutations in PTC uniformly result in the activation of the
MEK/ERK pathway.2,3 Of these genetic alterations, the BRAFV600E
mutation has been identiﬁed as the most common genetic event
related to PTC.4–6 PTC appears to have a homogenous molecular
signature in tumorigenesis compared with other human cancers,7
but it has wide variability in clinical behaviors.8 In fact, a subset of
PTC is clinically aggressive and fatal due to the refractory nature of
PTC to conventional radiation and drug treatment.9 Although
recent efforts to identify prognostic factors have helped to select
patients who need appropriate treatment modalities, the current
prognostic factors are not able to provide the molecular
information that is potentially useful for prognostic evaluation
and treatment of PTC.10,11
The Yes-associated protein 1 (YAP1) is a transcriptional
coactivator that binds to TEA domain family members in
mammals and acts as a downstream effector of the Hippo
pathway.12 The Hippo pathway is composed of the core kinases
Mst1/2 and Lats1/2 and two adapter proteins ww45 and Mats
(Mob); these components are involved in tumorigenesis through
a loss-of-function mechanism.13–15 The loss of Hippo signaling
components leads to the nuclear accumulation or aberrant
activation of endogenous YAP1,16,17 thus promoting the
expression of genes controlling a cell-autonomous role in
proliferation and cell-to-cell interactions. These effects were
demonstrated through the increase of organ size in Drosophila
and the increase of cell density in mouse embryos by YAP1
overexpression.12,18 It has consistently been shown that the YAP1
protein is overexpressed in a wide spectrum of human cancer cell
lines and primary tumors, including the lung, pancreatic, ovarian,
hepatocellular, colorectal and prostate carcinomas.16,19–21 More
importantly, the upregulation of YAP1 expression is a prognostic
maker in patients with nonsmall cell lung cancer and
hepatocellular carcinoma.21,22
Raf-1 directly interacts with MST2 and thereby inhibits
activating phosphorylation of MST2.23,24 Additionally, MST2
mediates a signaling pathway controlled by RASSF1A, Raf-1 and
Akt.25 Furthermore, cooperative oncogenic Ras–Raf signaling is
required to drive Yorkie/Scalloped-dependent epithelial tissue
overgrowth in Drosophila.26 However, the relationship between
BRAFV600E and Hippo signaling has been barely investigated.
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Recently, we reported that the oncogenic effect of BRAFV600E is
associated with the inhibition of MST1, a master kinase of the
Hippo tumor suppressor pathway, through direct interaction to
repress the activity of the RASSF1A–MST1–FoxO3 pathway in
BRAFV600E tumors.27 However, the YAP1 expression status and its
role in human thyroid cancer were not demonstrated, and
furthermore, the biological role of YAP1 in thyroid cancer in the
context of BRAFV600E activation remains to be determined. In this
study, we show that YAP1 is frequently overexpressed in thyroid
cancer and that its activation is related to the biological behavior
of thyroid cancer.
RESULTS
Nuclear expression of YAP1 is increased in human thyroid cancer
samples
To investigate the expression pattern of YAP1 in thyroid cancer,
we performed immunohistochemical (IHC) staining in parafﬁn-
embedded tissues, including normal thyroid tissues (42 cases), PTC
(131 cases), follicular adenoma (13 cases), follicular carcinoma
(44 cases) and anaplastic thyroid cancer (9 cases). PTC and
anaplastic thyroid cancer showed uniformly higher YAP1 staining
scores compared with normal thyroid tissues, follicular adenoma
and follicular carcinoma (Supplementary Table 1). Furthermore,
PTC demonstrated a statistically signiﬁcant increased expression
of YAP1 compared with normal thyroid tissue (Po0.001,
Figure 1a). Accordingly, the pattern of subcellular localization of
YAP1 in PTC can be classiﬁed into three groups: group 1, 54 cases
(41.2%) of PTC with nuclear YAP1; group 2, 48 cases (36.6%) with
cytoplasmic YAP1; and group 3, 29 cases (22.1%) with nuclear and
cytoplasmic YAP1 (Figure 1b). Interestingly, nuclear YAP1 showed
a statistically signiﬁcant association with the presence of
extrathyroidal extension (Supplementary Table 2, P¼ 0.046).
Furthermore, when groups 1 and 3 were combined into one
group, the statistical signiﬁcance of the association of YAP1 with
extrathyroidal extension was reinforced (Supplementary Table 3,
P¼ 0.017). Next, we compared the staining score and localization
pattern of YAP1 according to the BRAFV600E mutation status
(Supplementary Table 4). The YAP1 staining scores of BRAFV600E-
positive PTC (BRAFV600E (þ ) PTC) were statistically different from
those of BRAFV600E-negative PTC (BRAFV600E ( ) PTC, P¼ 0.031).
Remarkably, 88 cases (81.5%) of BRAFV600E (þ ) PTC showed a
strong staining intensity (score¼ 3), and 20 cases showed a
moderate staining intensity. The subcellular localization of YAP1 in
BRAFV600E (þ ) PTC also differed from that of BRAFV600E ( ) PTC
(Figure 1c, Po0.001). For BRAFV600E (þ ) PTC, group 1 included 50
Figure 1. Nuclear overexpression of YAP1 in thyroid cancer. (a) Comparison of the YAP1 staining scores between normal thyroid tissue and
PTC. The staining score was classified from 0 to 3 (see Materials and methods for a detailed description). (b) Subcellular localization of YAP1 in
PTC. (c) Comparison of the subcellular localization of YAP1 according to the presence or absence of BRAFV600E mutation. (d) The representative
figures of YAP1 staining in BRAFV600E (þ ) PTC composed of well-differentiated cell and poorly differentiated cell. Each upper figure and the
corresponding lower figure are taken at the same sites from the tissue samples. Red boxes indicate the magnified area at the next high power
field. *P-values are o0.001.
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cases (46.3%), group 2 consisted of 31 cases (28.7%) and group 3
included 27 cases (25%), whereas for BRAFV600E ( ) PTC, group 1
contained 4 cases (17.4%), group 2 contained 17 cases (73.9%) and
group 3 consisted of 2 cases (8.7%). Consistently, the 88 cases of
BRAFV600E (þ ) PTC with strong staining intensities showed nuclear
YAP1 localization: group 1, 39 cases (44.3%); group 2, 25 cases
(28.4%); and group 3, 24 cases (27.3%). The analyses of the
clinicopathological parameters showed that BRAFV600E (þ ) PTC
was more frequently accompanied with extrathyroidal extension
than BRAFV600E ( ) PTC (Supplementary Table 5, P¼ 0.037). These
observations suggested that the increased nuclear expression of
YAP1 might promote the invasion of BRAFV600E (þ ) PTC into
adjacent tissues.
E-cadherin, a member of the cadherin superfamily, ensures that
cells within tissues are bound together. E-cadherin-mediated cell
contact activates the Hippo pathway, resulting in the inhibition of
cell proliferation with cytosolic translocation of YAP1.28 However,
YAP1 was persistently detected in the nucleus of BRAFV600E (þ )
PTC (Figure 1d upper row), whereas E-cadherin was easily
detected in the cellular membrane, suggesting cell-to-cell
adhesion (Figure 1d lower row).
Thus, these clinical and IHC data suggest that nuclear
expression of YAP1 is able to affect the aggressiveness of
BRAFV600E (þ ) PTC tumors, including extrathyroidal extension,
independently from E-cadherin-mediated Hippo activation.
YAP1 is activated in the BRAFV600E (þ ) thyroid cancer cell lines,
8505C and K1, regardless of cell density
Based on the IHC results, we investigated whether nuclear YAP1 was
consistently detected in thyroid cancer cell lines using immuno-
ﬂuorescent staining. Nuclear YAP1 (red) was easily detected in TPC-1,
and HTH7 cells are BRAFV600E ( ) thyroid cancer cell lines at low cell
densities. However, the nuclear YAP1 signal disappeared while
membrane b-catenin (green) was strongly expressed along with the
cell membrane, suggesting cell-to-cell adhesion by high cell density
(Figure 2a). The change of YAP1 transcriptional activity according to
cell density was determined with real-time PCR for integrin beta 2
(ITGB2), which is known to be induced by YAP1 through a TEA
domain-dependent manner.29 As expected, ITGB2 was remarkably
decreased in TPC-1 cells at high cell densities (Supplementary
Figure 1A). In contrast, nuclear YAP1 was persistently detected even
at high cell densities in 8505C and K1 cells (BRAFV600E (þ ) thyroid
cancer cell lines), suggesting that the nuclear localization of YAP1 is
maintained regardless of cell density (Figure 2a). Interestingly, the
induction of ITGB2 in 8505C cells was markedly increased at high cells
densities over that observed at low cell densities (Supplementary
Figure 1B). At high cell densities, 8505C cells demonstrated a strong
induction of ITGB2 compared with TPC-1 cells (Figure 2c).
Next, we used the BRAFV600E- and BRAFWT-HEK293A cell lines to
investigate the effect of the BRAFV600E mutation on the subcellular
localization of YAP1. Although HEK293A cells are not derived from
Figure 2. Persistent nuclear localization of YAP1 in thyroid cancer cells regardless of cell density. (a, b) Representative immunofluorescence
figures demonstrate the subcellular localization of YAP1 in thyroid cancer cell lines (a), BRAFWT- and BRAFV600E-HEK293A cells (b). (c) Real-time
PCR data showed mRNA expressions of YAP1, ITGB2 and b-catenin in TPC-1, 8505C, BRAFWT- and BRAFV600E-HEK293A cells under high cell
densities. *P-values areo0.05. Data represent the mean±s.d. of three independent experiments. (d) Summary of the subcellular localization
of YAP1 in the cell lines used in this study. (e) Representative immunofluorescence images present the subcellular localization of YAP1 in TPC-1
and 8505C cells transfected with LATS2 (1mg/well, 24 h).
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the thyroid, the function of the tumor suppressor p53 is reduced in
this cell line. This is similar to 8505C cell lines harboring an allelic
deletion of the p53 gene30 and to K1 cell lines with altered p53
function.31 Therefore, we postulated that the effects of the BRAFV600E
mutation are similar in the HEK293A, 8505C and K1 cell lines. BRAFWT-
HEK293A showed nuclear YAP1 at low cell densities and cytoplasmic
translocation of YAP1 at high cell densities (Figure 2b). In conjunction
with the altered YAP1 localization, the expression of ITGB2 was
decreased by high cell density growth (Supplementary Figure 2A). In
contrast, nuclear YAP1 was detected in both low and high cell
densities, and persistent ITGB2 induction was observed in BRAFV600E-
HEK293A (Figure 2b and Supplementary Figure 2B). At high cell
densities, BRAFV600E-HEK293A cells showed increased ITGB2 expres-
sion compared with BRAFWT-HEK293A cells (Figure 2c). In summary,
YAP1 was retained in the nucleus regardless of cell density in
BRAFV600E (þ ) cell lines such as 8505C, K1 and BRAFV600E-HEK293A,
whereas YAP1 shuttled between the nucleus and cytosol according
to cell density in BRAFV600E ( ) cell lines such as TPC-1, HTH7 and
BRAFWT-HEK293A (Figure 2d).
To verify that the Hippo signaling pathway is altered in 8505C
cells, we transfected TPC-1 and 8505C cells with LATS2 kinase to
inactivate YAP1 by enhancing its translocation from the nucleus to
the cytosol. As shown in Figure 2e, LATS2 initiated the cytosolic
translocation of YAP1 in TPC-1 cells but not in 8505C cells. This
observation indicates that the Hippo signaling pathway may be
suppressed in 8505C cells.
Nuclear YAP1 localization in thyroid cancer cells was not affected
by RAF kinase inhibitors
The gain-of-function mutation of BRAFV600E induces a molecular
structural change mimicking an active conformation.32 Therefore,
this mutation is associated with an increased kinase activity, which
is related to cellular transformation in NIH3T3 cells.4 On the basis
of this ﬁnding, various kinase inhibitors have been developed and
investigated in clinical trials.33,34 Thus, we studied whether a
broad-spectrum pan-RAF inhibitor (Sorafenib) and selective
BRAFV600E inhibitor (PLX4720) were able to inhibit the nuclear
localization of YAP1 in 8505C cells. In addition, we used MEK
inhibitors such as PD98059 and U0126 to verify the role of MEK/
ERK signaling in the regulation of YAP1 in BRAFV600E (þ ) 8505C
cells. As shown in Figure 3a, nuclear YAP1 was detected in 8505C
cells regardless of cell density, whereas b-catenin localized to
the cell membrane at high cell densities. Interestingly, YAP1 was
persistently detected in the nucleus after treatment with
Sorafenib, PLX4720, PD98059 or U0126 at both low and high cell
densities, even though these compounds effectively inhibited ERK
phosphorylation (Figure 3b). These data suggest that BRAFV600E is
Figure 3. The effects of RAF kinase inhibitors on YAP1 transactivation by BRAFV600E-activated 8505C cells. (a) 8505C cells under low or high cell
density were treated with Sorafenib (1 mM), PLX4720 (1 mM), PD98059 (50mM) or U0126 (1 mM) for 2 h. b-Catenin was used as a marker of cell-to-
cell contact, and nuclear staining was performed using 4, 6-diamidino-2-phenylindole (DAPI). (b) The results of western blot analyses to verify
the effect of ERK or YAP1 S127 phosphorylation by inhibitors. (c, d) The results of western blot analyses and immunofluorescence staining to
present the effect of YAP1 activation by BRAF silencing in 8505C cells. CTL, control; DMSO, dimethyl sulfoxide.
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able to retain nuclear YAP1 in the 8505C cells, but this retention is
not dependent on the kinase activities of the RAF and MEK/ERK
signaling pathways. In contrast, the silencing of BRAFV600E by
transfecting siBRAF resulted in an increase in the inactivating
phosphorylation (S127) and cytosolic translocation of YAP1 (Figures
3c and d). Thus, nuclear YAP1 is associated with the BRAFV600E
mutation but is not related to RAF kinase or MEK/ERK activity.
YAP1 promotes the migration of thyroid cancer cells in vitro
As YAP1 was retained in the nucleus in 8505C cells regardless of
cell density, we investigated the effect of YAP1 on tumor behavior
in these cells. To perform the in vitro cell viability assay, we
silenced YAP1 expression in 8505C cells (shYAP1-8505C) using a
shYAP1 plasmid-based RNA interfering technique (Supplementary
Figure 3A), and observed that shYAP1-8505C demonstrated no
differences in cell viability compared with control small hairpin
RNA-transfected 8505C cells (shCTL-8505C) (Supplementary
Figure 3B). However, in the scratch assays performed to determine
whether YAP1 affected the migration ability of BRAFV600E-activated
8505C cells, shYAP1-8505C showed a remarkably lower migration
rate compared with shCTL-8505C (46.2±7.4% vs 22.9±3.9%,
respectively, P¼ 0.009, Figures 4a and b). To verify the role of
YAP1 in thyroid cancer cell migration, we transfected TPC-1 cells
with YAP1 and YAP1 S127A vectors. The YAP1 S127A mutant is
independent from LATS1/2 and maintains a constitutive level of
transactivation.12 Wild-type YAP1-transfected TPC-1 cells showed
a higher migration rate than control TPC-1 cells (75.6±5.6%
vs 67.6±3.5%, respectively, P¼ 0.028). Moreover, YAP1 S127A-
transfected TPC-1 cells showed the highest migration rate (YAP1
S127A vs control; 97.1±0.6% vs 67.6±3.5%, P¼ 0.009, YAP1 S127A
vs WT; P¼ 0.05; Figures 4c and d). These in vitro experiments
demonstrate that YAP1 has a role in the invasion of thyroid cancer
cells in agreement with our human clinicopathological analysis.
Silencing of YAP1 reduced tumor size and decreased expression of
genes related to tumor aggressiveness in an orthotopic thyroid
cancer model
On the basis of the results from the clinical and in vitro data, we
decided to perform phenotype analyses using an orthotopic
thyroid cancer model to demonstrate that YAP1 promotes the
invasion of BRAFV600E-activated 8505C cells in vivo. Interestingly,
4 weeks after tumor cell injection (shYAP1-8505C or shCTL-8505C),
a gross inspection of the thyroid gland from shCTL-8505C-injected
mice (shCOM) demonstrated markedly enlarged thyroid tumors
accompanied with peritumoral bleeding (Figure 5a). The esti-
mated tumor volume of shCOM was signiﬁcantly larger than that
of shYAP1-8505C-injected mice (shYAM) (57.7±20.1 vs
3.3±2.5 cm3, respectively, P¼ 0.009, Figure 5b). The use of
Figure 4. The migration ability promoted by YAP1 in thyroid cancer cell lines. (a, b) The scratch assays were performed using shCTL-8505C and
shYAP1-8505C. At 12 h after scratching, the migration rates were calculated (the distance from the right to left border at 12 h divided by the
distance from the right to left border at the start time). (c, d) The scratch assays were performed using TPC-1 cells transfected with empty
vector, wild-type YAP1 (YAP1 WT) or YAP1 S127A. At 12 h after scratching, the migration rates were calculated. *P-values are o0.01. Data
represent the mean±s.d. of three independent experiments.
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orthotopic tumor models offers a similar microenvironment, cell
growth and metastatic pattern to that of human cancer compared
with subcutaneous tumor models.35 Consequently, the small
tumor volume of shYAM in this model indicates that YAP1 might
be related to the tumor aggressiveness of thyroid cancer, as
shown by the in vitro experiments.
Supporting the histological observations, the orthotopic model
showed a differential expression pattern of the ITGB2, L1 cell
adhesion molecule (L1CAM) and p53 between shCOM and shYAM
(Figure 5c). L1CAM was identiﬁed in the nervous system as a
member of the immunoglobulin superfamily. However, recent
studies reported that L1CAM is detected at the cell membrane of
invasive front of tumors, suggesting that L1CAM is
strongly associated with tumor invasion and progression.36 In
fact, L1CAM and YAP1 have been postulated as novel targets of
Wnt/b-catenin signaling.37,38 Furthermore, our group has
recently reported that L1CAM has an important role in
determining tumor behavior and chemosensitivity in anaplastic
thyroid cancers.39 On the basis of these ﬁndings, we postulated
that L1CAM and YAP1 might have synergistic effects on epithelial
to mesenchymal changes, resulting in the invasion of adjacent
normal tissues. Compatible with our idea, IHC staining
demonstrated membrane localization of L1CAM in shCOM tumor
cells. However, the expression level of L1CAM was remarkably
decreased and the subcellular localization of L1CAM was
mainly in the cytoplasm rather than membrane-localized in
shYAM thyroid tumors (Figure 5d). As 8505C cells have a mutated
p53, the expression of p53 represents the dedifferentiation of the
tumor cells.30 In our orthotopic model, p53 expression was
increased in tumors from shCOM compared with shYAM (Figures
5c and d).
Thus, orthotopic tumors derived from shYAP1-8505C cells were
small and the expression of L1CAM and p53 was reduced, which
suggests that YAP1 may affect the aggressiveness of thyroid
tumors.
Silencing of YAP1 resulted in decreased tumor invasion and
distant metastasis in an orthotopic thyroid cancer model
Next, we examined the invasive tumor front adjacent tissue
and analyzed the metastatic foci in the lungs from shCOM
and shYAM. shCOM showed tumor cells that had extensively
penetrated into the tracheal cartilage, resulting in the destruction
of the bronchial epithelium and ﬁnally inducing airway
distortion. Tumor cells of shCOM also strikingly inﬁltrated into
the esophageal submucosa, resulting in the destruction of the
esophageal muscle, which was replaced by tumor cells in
the invasion area (Figure 6a and Supplementary Figure 4A). In
contrast, shYAM showed minimal invasion along the trachea,
did not inﬁltrate into the submucosal glands and did not
Figure 5. The relation of YAP1 to molecular markers indicating tumor aggressiveness in BRAFV600E-activated 8505C cells injected thyroid
cancer. (a) Gross and microscopic inspection of thyroids from shCOM and shYAM. Arrows indicate thyroid tumors, and the red boxes indicate
the magnified areas at the next high power field. (b) The comparison of tumor volumes from shCOM (n¼ 6) and shYAM (n¼ 6). (c) Real-time
PCR data demonstrating the effect of YAP1 silencing in 8505C cells. P-values are o0.01. Data represent the mean±s.d. (d) IHC staining to
detect YAP1, L1CAM and p53 in thyroids from shCOM and shYAM. The red boxes indicate the magnified areas at the next high power field.
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affect airway patency. shYAM also demonstrated an intact
esophageal muscle (Figure 6a, shYAM). As expected, the invasive
front of the tumors from shCOM showed strong membranous
L1CAM expression (Figure 6b and Supplementary Figure 4B).
However, tumor cells of shYAM had lower expression levels of
L1CAM in the invasive front (Figure 6b). Consistent with the results
presented in Figure 5, p53 expression was markedly increased in
tumors from shCOM (Figure 6b).
To examine the role of YAP1 in tumor metastasis, we
characterized the metastatic foci in the lungs from shCOM
and shYAM. Upon gross inspection of the lungs, we found
metastatic foci in the lung from shCOM (Supplementary Figure 5).
Microscopic metastatic foci were detected in animals for both
tumor groups; however, when we counted and statistically
analyzed the data, the number of metastatic foci in shCOM was
markedly higher than that in shYAM (51.4±4.7 vs 21.8±4.4,
respectively, P¼ 0.009, Figure 6c). Furthermore, the IHC
study showed that cyclin D1 and p53 were remarkably
increased in the metastatic foci of shCOM compared with shYAM
(Figure 6d).
In summary, tumors derived from shYAP1-8505C cells were less
invasive and had fewer metastatic foci than the tumors derived
from shCTL-8505C cells. Taken together with the results of the IHC
study, these histological features suggest that YAP1 may have
roles in tumor invasion and in distant metastasis in patients with
thyroid cancer.
DISCUSSION
In this study, we used human samples, cell lines and orthotopic
models to investigate the role of YAP1 in thyroid cancer
(Supplementary Figure 6). We demonstrated that YAP1 is retained
in the nucleus in human thyroid cancer even when E-cadherin-
mediated activation of Hippo might be functional. Furthermore,
nuclear localization of YAP1 was positively associated with
extrathyroidal extension in cells harboring the BRAFV600E mutation.
In support of our clinical data, immunoﬂuorescent staining
consistently demonstrated that YAP1 is retained in the nucleus
in 8505C and K1 cells, which harbor the BRAFV600E mutation, at
high density. The Hippo pathway is an essential process for the
growth regulatory network of epithelial tissues to inhibit out-
growth of organ size40–42 and maintain the apico-basal cell
polarity.43,44 In this context, cell adhesion and cell junction
proteins induce the Hippo pathway to inactivate YAP1 via
LATS1/2 and turnoff YAP1-dependent transcriptional output.15 In
Drosophila, the binding of Fat, a protocadherin, with Ds leads to
the recognition of cell-to-cell contact, which may be the initial
Figure 6. The effect of YAP1 on tumor invasion and metastasis into adjacent tissues in BRAFV600E-activated 8505C cells injected thyroid cancer.
(a) The comparison of adjacent tissue invasion, such as esophagus and trachea, between shCOM and shYAM. Arrows indicate the invasive
front of the thyroid tumors, and the red boxes indicate the magnified areas at high power fields. (b) IHC staining of the magnified areas in a to
detect YAP1, L1CAM and p53 in the invasive fronts from shCOM and shYAM. (c) The comparison of the number of metastatic foci between
shCOM and shYAM (see Materials and methods for detail description). (d) IHC staining of magnified areas in Supplementary Figure 5 to detect
YAP1, L1CAM and cyclin D1 in the lungs from shCOM and shYAM.
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step of Hippo activation promoted by the Ex–Mer–Kibra
complex.45,46 In mammals, although the exact function of the
Fat and Ex homologs are not veriﬁed, Mer and RASSF, members of
the Ras effector protein family, activate Mst1/2, suggesting that
the sensors to detect cell-to-cell contact may be working to
activate the Hippo pathway.47,48 Thus, our clinical and in vitro data
suggest that nuclear retention of YAP1 in thyroid cancer might be
a signature event in the escape from organ size control systems.
Supporting our hypothesis, the real-time PCR data showed that
ITGB2, a YAP1-inducible gene, was markedly increased in 8505C
cells and in BRAFV600E-HEK293A cells even under high cell density.
Moreover, shYAP1-8505C cells also showed decreased mRNA
levels of ITGB2. In fact, YAP1 potently induces ITGB2 expression
through TEA domain family transcriptional factors,29 promoting
the epithelial–mesenchymal transition of tumor cells.49,50
Interestingly, when the TPC-1 and 8505C cell lines were
transfected with LATS2, which leads to inhibitory phosphorylation
(S127) of YAP1, and can thereby promote the translocation of
YAP1 from the nucleus to the cytoplasm, YAP1 was cytosolic in
TPC-1 cells, whereas it was retained in the nucleus in 8505C cells.
This suggests that Hippo signaling might be aberrant in 8505C
cells, which harbor the BRAFV600E mutation. In addition to Mst1/2-
Lats1/2-mediated YAP1 regulation, YAP1 is regulated by cross-talk
with angiomotin/angiomotin-like 151,52 or mechanical cues
delivered by Rho and stress ﬁbers.53 Therefore, we may suspect
that BRAFV600E promotes YAP1 transactivation via the regulation of
these factors. However, the relationship of BRAFV600E with
angiomotin/angiomotin-like 1 has not been clariﬁed in vitro or
in vivo. Furthermore, maintenance of actin stress ﬁbers in
ﬁbroblasts by Rho-associated coiled-coil-containing protein
kinase II is regulated by BRAF in a MEK-dependent manner.54
However, treatment with the pan-RAF kinase inhibitor (Sorafenib),
the BRAFV600E kinase inhibitor (PLX4720) or MEK inhibitors such as
PD98059 and U0126 did not abolish the nuclear accumulation of
YAP1 in BRAFV600E (þ ) 8505C cells. In contrast, BRAFV600E silencing
promoted S127 phosphorylation and the cytosolic localization of
YAP1. Therefore, a possible regulatory mechanism of YAP1 via
BRAFV600E is that the Hippo signal is directly inactivated
by BRAFV600E through the MST1/2 interaction independently
from the BRAFV600E kinase activity, which our group has
previously reported.27
Additionally, our study demonstrated that YAP1 was clearly
associated with tumor invasion in vitro and in vivo. Based on the
results of the in vitro cell viability assay, the cell viability of the two
cell lines, shCTL-8505C and shYAP1-8505C, was identical. However,
a scratch assay suggested that YAP1 deletion or overexpression
affected cell mobility in 8505C and TPC-1 thyroid cancer cell lines,
respectively, as seen in other models, such as in Gbg signaling or
15-hydroxyprostaglandin dehydrogenase.55,56 Furthermore, an
orthotopic mouse model demonstrated that the deletion of
YAP1 modiﬁed tumor behaviors and generated a more favorable
outcome. As discussed, YAP1 inactivation by the Hippo pathway
might have a pivotal role in the control of cell proliferation, and
may thus prevent tumorigenesis, which was strongly supported by
the liver-speciﬁc ablation of ww45 (adapter for Hippo kinase).57
From this point of view, previous studies have reported that
overexpression of YAP1 was highly associated with poor prognosis
in patients with hepatocellular carcinoma, ovarian serous tumors
or gastric cancer.19–21 However, the multiple steps of
carcinogenesis, such as proliferation, invasion and even
metastasis, have not been observed in a single YAP1 animal
model to understand how it contributes to cancer cell biology at
each step. Remarkably, increased expression of L1CAM was
detected in primary sites of shCOM, and mutated p53, as a
hallmark of undifferentiated carcinoma, was increased in the
primary sites and metastatic lesions of shCOM compared with
shYAM. Furthermore, nuclear cyclin D1 was only observed in the
metastatic lesions of shCOM. These microscopic observations and
IHC data suggested that the deletion of YAP1 affected the
molecular signatures required by individual carcinogenic steps,
such as L1CAM for invasion, p53 for dedifferentiation and cyclin
D1 for the establishment of metastasis.58 Thus, thyroid cancers
may require YAP1 activity to gain the aggressive features
necessary to invade adjacent tissue and metastasize to distant
organs in vivo.
In conclusion, nuclear YAP1 would appear to be associated with
the extrathyroidal extension of thyroid cancer in patients with
BRAFV600E (þ ) PTC and with aggressive features such as migration,
local invasion and distant metastasis in in vitro and in vivo models.
Furthermore, the nuclear activation of YAP1 was maintained in
8505C and K1 cells, and resistant to RAF, BRAFV600E and MEK
inhibitors. Therefore, the YAP1 silencing or inhibition might be a
future therapeutic target in aggressive thyroid cancers.
MATERIALS AND METHODS
Selection of patients and analysis of clinicopathological data
Thyroid tissue specimens were obtained from 197 patients who underwent
surgery from 2004 to 2005 at the Center for Endocrine Surgery, Chungnam
National University Hospital, Daejeon, Korea. Microscopically normal
thyroid tissues were obtained from patients who underwent thyroidect-
omy because they had benign thyroid diseases (7 cases of follicular
adenoma and 35 cases of nodular hyperplasia). Patient information and
clinicopathological parameters were analyzed. For staging PTC samples,
the Tumor Node Metastasis classiﬁcation of the International Union
Against Cancer (UICC) was used. All protocols were approved by the
institutional review board.
DNA isolation and pyrosequencing
Genomic DNA from parafﬁn-embedded thyroid tissue specimens consist-
ing of more than 90% tumor cells was prepared from ﬁve 10mm-thick
sections after microdissection. After the sections were deparafﬁnized,
genomic DNA was isolated using the EZ1 DNA Tissue Kit (Qiagen,
Chatsworth, CA, USA). Genomic DNA ampliﬁcation, the puriﬁcation of the
ampliﬁed products and pyrosequencing were performed as previously
described.59
Cell lines
HEK293A and 8505C cells were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). K1 cells were obtained from the
European Collection for Cell Cultures (ECACC, Salisbury, UK). HTH7 and
TPC-1 cells were provided by Dr M Santoro (Universita` di Napoli Federico II,
Naples, Italy) and Dr Masahide Takahashi (Nagoya University, Nagoya,
Japan), respectively. HEK293 cell lines stably expressing BRAFV600E or wild-
type BRAF (BRAFV600E-HEK293A and BRAFWT-HEK293A, respectively) were
generated using the ViraPower lentiviral expression system (Invitrogen,
Carlsbad, CA, USA). The 8505C YAP1 silenced (shYAP1-8505C) and control
small hairpin RNA (shCTL-8505C) cell lines were generated using MISSON
small hairpin RNA lentiviral transduction particles (Sigma-Aldrich, St Louis,
MO, USA).
Cell culture and transfection
TPC-1, HTH7 and K1 cells were cultured in Dulbecco’s modiﬁed Eagle
medium with 10% fetal bovine serum. 8505C cells were cultured in
RPMI1640. TPC-1 and 8505C cells were grown in six-well plates and
transfected with FLAG-LATS2 (1mg/well) for 24 h using Lipofectamine PLUS
(Invitrogen). 8505C cells were transfected with 20 pmol Stealth siRNA or
siBRAF (Invitrogen) oligomers in 50 ml Opti-MEM I using Lipofectamine
RNAiMAX (Invitrogen). All experiments were performed in duplicate and
were repeated at least three times.
Immunohistochemistry
Parafﬁn-embedded tissue samples were prepared for IHC staining using a
standard protocol.17 The primary antibodies used in this study were anti-
YAP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-E-cadherin (Cell
Signaling Technology, Beverly, MA, USA), anti-L1CAM (Abcam, Cambridge,
UK), anti-p53 (Dako, Copenhagen, Denmark) and anti-cyclin D1 (Dako).
Negative controls were incubated with phosphate-buffered saline instead
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of a primary antibody, and no positive staining was observed. In addition,
positive controls were performed with sections of lung squamous cell
carcinoma and stained for YAP1, p53 and cyclin D1, as well as nerve
bundles for L1CAM and breast ductal carcinoma for E-cadherin. To classify
the IHC results for the human samples, we used the following scoring
system: 0, no staining; 1, weak staining in the focal area; 2, moderate
staining in most cells; and 3, strong staining in most cells. The IHC results
were evaluated by two independent pathologists (JUL and JMK).
RNA isolation and real-time PCR
RNA isolation and real-time PCR were performed according to the
manufacturer’s protocol. Brieﬂy, total RNA was extracted using Trizol
(Invitrogen), and complementary DNA (cDNA) was prepared from total
RNA using M-MLV Reverse Transcriptase (Invitrogen) and oligo-dT primers
(Promega, Madison, WI, USA). Real-time PCR was performed using cDNA,
QuantiTect SYBR Green PCR Master Mix (Qiagen, Valencia, CA, USA) and
speciﬁc primers (Supplementary Table 6). The relative expression was
calculated using the Rotor-Gene 6000 real-time rotary analyzer software
(Version 1.7, Corbett Life Science, Sydney, Australia). Real-time PCR
experiments were performed in triplicate and were repeated three times.
Immunoﬂuorescence staining
The cells were plated on coverslips in six-well plates. Low conﬂuence cells
were plated at 1 105 cells/well, and high conﬂuence cells were plated at
5 105 cells/well. After 3 days, the cells were ﬁxed and permeabilized
using conventional methods. Then, the cells were incubated with anti-
YAP1 (Santa Cruz Biotechnology) and anti-b-catenin (Santa Cruz Biotech-
nology) antibodies at a 1:100 dilution in 3% bovine serum albumin for 24 h
at 4 1C. After washing, cells were incubated with Cy2-conjugated pure goat
anti-mouse and TRITC (Rhodamine)-conjugated pure goat anti-rabbit
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). Nuclei
were stained using 4, 6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich).
After washing the cells, cells on the coverslips were mounted on glass
slides using mounting medium (Sigma-Aldrich) and observed using a laser-
scanning confocal microscope (Olympus Corp., Tokyo, Japan). All experi-
ments were performed in duplicate and were repeated at least ﬁve times.
Cell viability assay
shCTL-8505C and shYAP1-8505C cells were plated in 96-well plates at
1 102 cells/well in 200ml of RPMI1640. At the indicated times, an MTT
solution (Sigma-Aldrich) was added to the plated cells. During 96 h, we
measured the absorbance at 595 nm using an E max precision microplate
reader (Molecular Devices, Sunnyvale, CA, USA). Experiments were
performed in triplicate and were repeated at least three times.
Immunoblot analysis
Cells were lysed in lysis buffer, and the cell lysates were separated using
SDS–polyacrylamide gel electrophoresis. After the proteins were trans-
ferred to a nitrocellulose (NS) membrane (Amersham Biosciences, Freiburg,
Germany), the membranes were blocked with 5% skim milk and incubated
with the indicated primary antibodies overnight at 4 1C, and with the
indicated secondary antibodies for 1 h at room temperature. The
immunoreactive bands were developed using peroxidase-conjugated
secondary antibodies (Phototope-HRP Western Blot Detection Kit, New
England Biolabs, Beverly, MA, USA).
Scratch assay
shCTL-8505C and shYAP1-8505C cells were plated in six-well plates at
5 105 cells/well. After 3 days, the cell surface in three places were
scratched using a p200 pipette tip. Additionally, TPC-1 cells were plated in
six-well plates and after 24 h, were transfected with pCMV-HA-YAP1 or
pCMV-HA-YAP1 S127A using Lipofectamine PLUS (Invitrogen). Next, the cell
surface was scratched using a p200 pipette tip after 2 days. The cells
were observed after 12 h using an Olympus IX71 microscope (Olympus).
Human cDNAs for YAP1 were cloned into pDK-Flag2 or pCMV-HA
(HA, hemagglutinin), which had been modiﬁed from pcDNA3.1 or pcDNA3
(Invitrogen). Site-directed PCR mutagenesis was used to introduce the
missense change S127A into the YAP1 sequence.40 Migration rates were
calculated using the following equation: (full-length–scratched-length)/full-
length 100. Image analysis was performed using the ImageJ v1.42q
software (National Institutes of Health, USA). All experiments were
performed in triplicate and were repeated two times.
Orthotopic mouse model of thyroid cancer
Eight-week-old male nude mice were purchased from Japan SLC Inc.
Before injection of the cell lines into the mice, shCTL-8505C and shYAP1-
8505C cells were diluted to 1 105 cells/ml in RPMI1640. Each cell line was
injected into six mice. To inject 5 ml (5 105) of cells into the right thyroid,
a 33-gauge beveled needle (World Precision Instruments Inc., Sarasota, FL,
USA) and a 100-ml nanoﬁl syringe (World Precision Instruments Inc.) were
used. The mice were killed 4 weeks after injection, and tumor volumes
were calculated using the established equation: lengthwidth2 0.5.60
Thyroid glands and lungs from the mice were placed in formalin solution,
and each tissue was embedded in parafﬁn. The metastatic foci were
counted on 100 randomly selected high power ﬁelds in each experimental
group. All animal procedures were performed under the guidelines of the
Institutional Animal Care and Use Committee of the Chungnam National
University School of Medicine.
Statistical analysis
Group comparisons of categorical variables were evaluated using the
w2 test or linear-by-linear association. Comparisons of average means were
performed with the independent sample t-test, one-way analysis of
variance or Mann–Whitney U-test. All reported P-values are two sided.
Analyses were performed using SPSS Versions 18.0 for Windows.
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